Research Article

Patient Complications after Interscalene Block: A Retrospective Comparison of Liposomal Bupivacaine to Nonliposomal Bupivacaine

Table 9

Procedure summary table; values presented are N (%).

CovariateOverallLBNon-LB
(N = 1518)(N = 784)(N = 734)

Arthrodesis2 (0.1%)2 (0.3%)0 (0.0%)
Arthroscopic bankart/labral74 (4.9%)27 (3.4%)47 (6.4%)
Arthrosocopy arthrodesis1 (0.1%)0 (0.0%)1 (0.1%)
Arthrosocopy biceps68 (4.5%)27 (3.4%)41 (5.6%)
Arthrosocopy biopsy12 (0.8%)5 (0.6%)7 (1.0%)
Capsular repair17 (1.1%)9 (1.1%)8 (1.1%)
Clavicle fracture22 (1.4%)4 (0.5%)18 (2.5%)
Distal clavicle1 (0.1%)0 (0.0%)1 (0.1%)
Elbow fracture3 (0.2%)1 (0.1%)2 (0.3%)
Hardware removal59 (3.9%)41 (5.2%)18 (2.5%)
Humerus fracture46 (3.0%)28 (3.6%)18 (2.5%)
I and D14 (0.9%)6 (0.8%)8 (1.1%)
Manipulation/reduction6 (0.4%)0 (0.0%)6 (0.8%)
Open biceps2 (0.1%)1 (0.1%)1 (0.1%)
Open instability surgery23 (1.5%)19 (2.4%)4 (0.5%)
Open RCR1 (0.1%)0 (0.0%)1 (0.1%)
RCR565 (37.2%)282 (36.0%)283 (38.6%)
Resurfacing2 (0.1%)1 (0.1%)1 (0.1%)
Reverse TSA157 (10.3%)89 (11.4%)68 (9.3%)
Reverse TSA revision49 (3.2%)36 (4.6%)13 (1.8%)
Simple arthroscopy139 (9.2%)68 (8.7%)71 (9.7%)
Triceps1 (0.1%)1 (0.1%)0 (0.0%)
TSA237 (15.6%)130 (16.6%)107 (14.6%)
TSA revision14 (0.9%)5 (0.6%)9 (1.2%)

LB: liposomal bupivacaine.